105 related articles for article (PubMed ID: 38742955)
1. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation.
Gagelmann N; Schuh C; Flossdorf S; Kunadt D; Stelljes M; Blau IW; Brecht A; Bethge W; Schroeder T; Wulf G; Sala E; Bug G; Fleischhauer K; Kröger N;
Am J Hematol; 2024 May; ():. PubMed ID: 38742955
[TBL] [Abstract][Full Text] [Related]
2. Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study.
Pasic I; Moya TA; Remberger M; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38648898
[TBL] [Abstract][Full Text] [Related]
3. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
Shimoni A; Labopin M; Savani B; Hamladji RM; Beelen D; Mufti G; Socié G; Delage J; Blaise D; Chevallier P; Forcade E; Deconinck E; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2018 Apr; 24(4):751-757. PubMed ID: 29247780
[TBL] [Abstract][Full Text] [Related]
5. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Beelen DW; Stelljes M; Reményi P; Wagner-Drouet EM; Dreger P; Bethge W; Ciceri F; Stölzel F; Junghanß C; Labussiere-Wallet H; Schaefer-Eckart K; Grigoleit GU; Scheid C; Patriarca F; Rambaldi A; Niederwieser D; Hilgendorf I; Russo D; Socié G; Holler E; Glass B; Casper J; Wulf G; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; La Rocca U; Finke J; Benedetti F; Pichlmeier U; Klein A; Baumgart J; Markiewicz M
Am J Hematol; 2022 Aug; 97(8):1023-1034. PubMed ID: 35617104
[TBL] [Abstract][Full Text] [Related]
6. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
7. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
8. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
[TBL] [Abstract][Full Text] [Related]
9. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
Holtick U; Herling M; Pflug N; Chakupurakal G; Leitzke S; Wolf D; Hallek M; Scheid C; Chemnitz JM
Ann Hematol; 2017 Mar; 96(3):479-487. PubMed ID: 27909887
[TBL] [Abstract][Full Text] [Related]
10. Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
Kim SH; Ji YS; Yun J; Choi SH; Lim SH; Kim CK; Park SK
J Korean Med Sci; 2023 Sep; 38(36):e281. PubMed ID: 37698206
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Chhabra S; Narra RK; Wu R; Szabo A; George G; Michaelis LC; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Pasquini MC; Rizzo RD; Saber W; Shah NN; Shaw BE; Hamadani M; Hari PN
Biol Blood Marrow Transplant; 2020 May; 26(5):893-901. PubMed ID: 31982543
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
13. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
Joseph J; Srour SA; Milton DR; Ramdial JL; Saini NY; Olson AL; Bashir Q; Oran B; Alousi AM; Hosing C; Qazilbash MH; Kebriaei P; Shpall EJ; Champlin RE; Popat UR
Transplant Cell Ther; 2023 Dec; 29(12):770.e1-770.e6. PubMed ID: 37742746
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
[TBL] [Abstract][Full Text] [Related]
16. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Zhu S; Liu G; Liu J; Chen Q; Wang Z
Front Oncol; 2020; 10():591363. PubMed ID: 33425740
[TBL] [Abstract][Full Text] [Related]
18. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial.
Sykora KW; Beier R; Schulz A; Cesaro S; Greil J; Gozdzik J; Sedlacek P; Bader P; Schulte J; Zecca M; Locatelli F; Gruhn B; Reinhardt D; Styczynski J; Piras S; Fagioli F; Bonanomi S; Caniglia M; Li X; Baumgart J; Kehne J; Mielcarek-Siedziuk M; Kalwak K
Bone Marrow Transplant; 2024 Jan; 59(1):107-116. PubMed ID: 37925531
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis.
Wu W; Xue N; Yang H; Gao P; Guo J; Han D
J Pediatr Hematol Oncol; 2023 Oct; 45(7):370-376. PubMed ID: 37526377
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
Claudiani S; Marktel S; Piemontese S; Assanelli A; Lupo-Stanghellini MT; Carrabba M; Guggiari E; Giglio F; De Freitas T; Marcatti M; Bernardi M; Corti C; Peccatori J; Lunghi F; Ciceri F
Hematol Oncol; 2016 Sep; 34(3):154-60. PubMed ID: 25469485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
